Wall Street Zen Upgrades ICU Medical (NASDAQ:ICUI) to “Buy”

by · The Markets Daily

ICU Medical (NASDAQ:ICUI – Get Free Report) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Monday.

ICUI has been the subject of several other research reports. Piper Sandler lifted their target price on shares of ICU Medical from $153.00 to $172.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ICU Medical in a research note on Wednesday, October 8th. Finally, KeyCorp boosted their price target on ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, ICU Medical currently has an average rating of “Moderate Buy” and a consensus target price of $175.67.

Read Our Latest Report on ICU Medical

ICU Medical Price Performance

NASDAQ:ICUI opened at $153.23 on Monday. The company has a 50-day moving average of $145.91 and a 200-day moving average of $132.39. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.19 and a current ratio of 2.45. The company has a market capitalization of $3.78 billion, a price-to-earnings ratio of -494.27 and a beta of 0.80. ICU Medical has a 52 week low of $107.00 and a 52 week high of $175.51.

ICU Medical (NASDAQ:ICUI – Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $2.03 EPS for the quarter, beating analysts’ consensus estimates of $1.43 by $0.60. The firm had revenue of $533.30 million for the quarter, compared to analyst estimates of $511.46 million. ICU Medical had a positive return on equity of 7.71% and a negative net margin of 0.32%.The business’s quarterly revenue was down 8.9% compared to the same quarter last year. During the same period last year, the company earned $1.59 EPS. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. As a group, equities research analysts anticipate that ICU Medical will post 4.11 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Virginia Ruth Sanzone sold 930 shares of the stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $142.34, for a total transaction of $132,376.20. Following the completion of the sale, the vice president owned 5,456 shares of the company’s stock, valued at approximately $776,607.04. This represents a 14.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Elisha W. Finney sold 1,285 shares of the stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $140.42, for a total transaction of $180,439.70. Following the sale, the director directly owned 3,995 shares of the company’s stock, valued at $560,977.90. The trade was a 24.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ICUI. Simon Quick Advisors LLC bought a new position in shares of ICU Medical in the second quarter worth about $275,000. AlphaQuest LLC grew its holdings in ICU Medical by 3,058.3% during the 2nd quarter. AlphaQuest LLC now owns 1,516 shares of the medical instruments supplier’s stock valued at $200,000 after buying an additional 1,468 shares in the last quarter. Aaron Wealth Advisors LLC bought a new stake in shares of ICU Medical during the third quarter valued at approximately $521,000. Magnetar Financial LLC purchased a new position in shares of ICU Medical in the second quarter worth $378,000. Finally, Hussman Strategic Advisors Inc. lifted its holdings in shares of ICU Medical by 40.0% in the second quarter. Hussman Strategic Advisors Inc. now owns 29,400 shares of the medical instruments supplier’s stock worth $3,885,000 after buying an additional 8,400 shares in the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

About ICU Medical

(Get Free Report)

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

Recommended Stories